
-
Veru Pharma NasdaqCM:VERU Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Location: 2916 North Miami Avenue, Miami, FL, 33127, United States | Website: https://verupharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
59.92M
Cash
19.62M
Avg Qtr Burn
-7.27M
Short % of Float
11.89%
Insider Ownership
14.19%
Institutional Own.
33.02%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ENTADFI™ (tadalafil and finasteride) Details Benign prostatic hyperplasia (BPH) | Approved Update | |
Enobosarm +/- abemaciclib Details HER2-expressing cancers, ER+/HER2- breast cancer | Phase 3 Update | |
Sabizabulin (Veru-111) Details COVID-19 | Phase 3 Update | |
Enobosarm +GLP-1 drugs [Ozempic® + Wegovy® + Mounjaro®] Details Obesity Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
VERU-100 Details Prostate cancer, Cancer | Failed Discontinued | |
Zuclomiphene citrate Details Hot flashes | Failed Discontinued | |
Sabizabulin (VERU-111) Details Castration-resistant prostate cancer | Failed Discontinued | |
Sabizabulin (VERU-111) + Enobosarm Details Triple-negative breast cancer , Cancer | Failed Discontinued |